Association of 15-hydroxyprostaglandin dehydrogenate and poor prognosis of obese breast cancer patients

Ruxing Wu; Tao Liu; Peiwen Yang; Xiyou Liu; Fei Liu; Ya Wang; Huihua Xiong; Shiying Yu; Xiaoyuan Huang; Liang Zhuang

doi:10.18632/oncotarget.15280

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Association of 15-hydroxyprostaglandin dehydrogenate and poor prognosis of obese breast cancer patients

Ruxing Wu, Tao Liu, Peiwen Yang, Xiyou Liu, Fei Liu, Ya Wang, Huihua Xiong, Shiying Yu, Xiaoyuan Huang and Liang Zhuang _

PDF | HTML | How to cite

Oncotarget. 2017; 8:22842-22853. https://doi.org/10.18632/oncotarget.15280

Metrics: PDF 1565 views | HTML 1505 views | ?

Abstract

Ruxing Wu1,*, Tao Liu2,*, Peiwen Yang1, Xiyou Liu3, Fei Liu3, Ya Wang1, Huihua Xiong3, Shiying Yu3, Xiaoyuan Huang1, Liang Zhuang3

1Department of Obstetrics and Gynecology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

2Department of Pediatrics, Aflac Cancer Center and Blood Disorders Service, Emory University School of Medicine, Atlanta, GA, USA

3Cancer Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

*These authors contributed equally to this work

Correspondence to:

Liang Zhuang, email: [email protected]

Keywords: HPGD, breast cancer, obese, prognosis

Received: August 02, 2016 Accepted: January 27, 2017 Published: February 11, 2017

ABSTRACT

In order to explore the new mechanism that obesity worsens the prognosis of breast cancer, we reanalyzed the data about gene expression of normal, overweight, and obese breast cancer patients to explore potential genes and validate its function by clinical and experimental data. The fold change of 15-hydroxyprostaglandin dehydrogenate (HPGD) gene which displayed declining trend with BMI increase was 0.46 in obese versus normal weight patients. HPGD protein was highest expressed in normal weight group and lowest expressed in obese group. The rate of positive lymph nodes was 67% in low expression of HPGD group and 35% in high expression of HPGD group. The recurrence-free survival (RFS) rate and overall survival (OS) rate of 5 years had significant difference between low expression of HPGD group and high expression of HPGD group. Obesity dramatically decreased the RFS rate and OS rate of 5 years. Down regulation of HPGD expression could increase the migration and proliferation ability of breast cancer cell line MCF-7. Taken together, our results indicate that low expression of HPGD may be a reason for poor prognosis of obese breast cancer patients.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 15280

Publication Alerts

Research Papers:

Association of 15-hydroxyprostaglandin dehydrogenate and poor prognosis of obese breast cancer patients

Abstract